Biotech RadarJobs updated

COMPANY

Neumedicines Inc.

neumedicines.com ↗

Past trials only

Profile checked Oct 10, 2026

Keywords: Cutaneous T Cell Lymphoma Mycosis Fungoides Sézary Syndrome Colostomy Stoma Lymphoma, Large B-Cell, Diffuse (DLBCL) NM-IL-12

5Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage Chemotherapy source ↗
  2. Trial start Phase 2: NM-IL-12 (rHuIL-12) in Subjects With Open Surgical Wounds source ↗
  3. Trial start Phase 2: NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) source ↗
  4. Trial start Phase 2: Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation Syndrome source ↗
  5. Trial start Phase 1: Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure source ↗

Clinical trials (lead sponsor) 5

RecordTitlePhaseStatusStartPrimary completion
NCT02542124NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT)Phase 2Unknown status (ClinicalTrials.gov)2015-122019-02 (estimated)
NCT01742221Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation CountermeasurePhase 1Completed2012-082012-11 (actual)
NCT02544061NM-IL-12 (rHuIL-12) in Subjects With Open Surgical WoundsPhase 2CompletedMar 1, 2016Oct 31, 2017 (actual)
NCT02343133Safety Study of HemaMax™ (rHuIL-12) to Treat Acute Radiation SyndromePhase 2Completed2015-012016-04 (actual)
NCT02544724NM-IL-12 (rHuIL-12) In Relapsed/Refractory Diffuse Large B- Cell Lymphoma (DLBCL) Undergoing Salvage ChemotherapyPhase 2Unknown status (ClinicalTrials.gov)2016-112017-08 (estimated)
Feedback